Lisata Therapeutics, Inc.

LSE:0HS8 Stock Report

Market Cap: US$31.3m

Lisata Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Dave Mazzo

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage48.0%
CEO tenure10yrs
CEO ownership1.2%
Management average tenure4.3yrs
Board average tenure9.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dave Mazzo's remuneration changed compared to Lisata Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$21m

Jun 30 2024n/an/a

-US$21m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$1mUS$676k

-US$21m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$54m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$650k

-US$54m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$24m

Dec 31 2021US$1mUS$631k

-US$27m

Sep 30 2021n/an/a

-US$26m

Jun 30 2021n/an/a

-US$25m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$1mUS$613k

-US$8m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$19m

Dec 31 2019US$2mUS$597k

-US$19m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018US$2mUS$594k

-US$16m

Compensation vs Market: Dave's total compensation ($USD1.41M) is above average for companies of similar size in the UK market ($USD349.90K).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.

CEO

Dave Mazzo (67 yo)

10yrs

Tenure

US$1,408,382

Compensation

Dr. David J. Mazzo, also known as Dave, B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph D., served as Independent Non Executive Chairman at Visioneering Technologies, Inc. since February 28, 2020 until February 29,...

Leadership Team

NamePositionTenureCompensationOwnership
David Mazzo
President10yrsUS$1.41m1.25%
$ 390.3k
Kristen Buck
Executive VP of R&D and Chief Medical Officer3.3yrsUS$969.82k0.75%
$ 233.8k
James Nisco
Senior VP of Finance3.8yrsno data0.041%
$ 13.0k
Tariq Imam
Vice President of Business Development & Operations and Corporate Counsel2yrsno datano data
Gregory Berkin
Chief Information & Data Protection Officer4.3yrsno datano data
John Menditto
Vice President of Investor Relations & Corporate Communications7.1yrsno datano data
Gail Holler
Vice President of Human Resources6yrsno datano data
William Sietsema
Vice President of Global Regulatory Affairsno dataUS$400.18kno data

4.3yrs

Average Tenure

65yo

Average Age

Experienced Management: 0HS8's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Mazzo
President10yrsUS$1.41m1.25%
$ 390.3k
Steven Klosk
Independent Director10.5yrsUS$120.00k0.0052%
$ 1.6k
Gregory Brown
Independent Chairman of the Board8.3yrsUS$149.50k0.0033%
$ 1.0k
Heidi Henson
Independent Director2.3yrsUS$124.00k0%
$ 0
Gerald Nepom
Member of Type 1 Diabetes Scientific Advisory Boardno datano datano data
Robert Negrin
Immune Modulation Program Advisorno datano datano data
Robert Korngold
Immune Modulation Program Advisorno datano datano data
David Pearce
Member of Type 1 Diabetes Scientific Advisory Boardno datano datano data
David Horwitz
Immune Modulation Program Advisorno datano datano data
David Peritt
Immune Modulation Program Advisorno datano datano data
Noel Warner
Immune Modulation Program Advisorno datano datano data
Kevan Herold
Member of Type 1 Diabetes Scientific Advisory Boardno datano datano data

9.1yrs

Average Tenure

67yo

Average Age

Experienced Board: 0HS8's board of directors are considered experienced (9.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 15:41
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lisata Therapeutics, Inc. is covered by 14 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jan WaldBenchmark Company
Kumaraguru RajaBrookline Capital Markets
Brian Kemp DolliverBrookline Capital Markets